Advances in the discovery of activin receptor-like kinase 5 (ALK5) inhibitors

Bioorg Chem. 2024 Apr 3;147:107332. doi: 10.1016/j.bioorg.2024.107332. Online ahead of print.ABSTRACTActivin receptor‑like kinase-5 (ALK5) is an outstanding member of the transforming growth factor-β (TGF-β) family. (TGF-β) signaling pathway integrates pleiotropic proteins that regulate various cellular processes such as growth, proliferation, and differentiation. Dysregulation within the signaling pathway can cause variety of diseases, such as fibrosis, cardiovascular disease, and especially cancer, rendering ALK5 a potential drug target. Hence, various small molecules have been designed and synthesized as potent ALK5 inhibitors. In this review, we shed light on the current ATP-competitive inhibitors of ALK5 through diverse heterocyclic based scaffolds that are in clinical or pre-clinical phases of development. Moreover, we focused on the binding interactions of the compounds to the ATP binding site and the structure-activity relationship (SAR) of each scaffold, revealing new scopes for designing novel candidates with enhanced selectivity and metabolic profiles.PMID:38581966 | DOI:10.1016/j.bioorg.2024.107332
Source: Bioorganic Chemistry - Category: Chemistry Authors: Source Type: research